Brief Reports Y oung children born to HIV-infected (HIV+) mothers in TBendemic settings experience high rates of TB disease, despite maternal combination antiretroviral therapy and infant BCG vaccination.
MATERIALS AND METHODS

Study Population
The parent study, IMPAACT P1041, was a multi-centered, phase II-III randomized, double-blind, placebo-controlled trial comparing pre-exposure IPT to placebo in HIV+ and HIV-exposed uninfected (HEU) infants.
2 BCG-vaccinated infants without reported TB exposure were randomized to receive daily INH or placebo for 96 weeks and followed for an additional 96 weeks. This substudy enrolled children followed in Cape Town either who had completed 96 weeks of study drug and were in follow-up or who were receiving randomized study drug for planned discontinuation at the next scheduled study visit. Participants in the parent study for <12 weeks were excluded. Written informed consent was obtained for participation in the substudy, and the protocol was approved by the Research Ethics Committee at Stellenbosch University (HREC N08/08/234).
Data Collection
At substudy enrolment, sociodemographic (age, sex, ethnicity) and clinical data (HIV-infection status, combination antiretroviral therapy use, TB exposure, prior TB diagnosis, anthropometric measurements) were collected. Participants had blood drawn for QuantiFERON-TB Gold In-Tube ELISA (QFT; Cellestis Limited, Carnegie, Victoria, Australia) at enrollment and after 1 year of follow-up. Laboratory technicians blinded to clinical data completed QFT assays according to the manufacturers' guidelines.
Data Analysis
Demographic and clinical characteristics of the HIV+ and HEU cohorts were summarized using descriptive statistics. Positive, negative and indeterminate results for QFT assays were defined according to the manufacturer's guidelines. Missing and indeterminate QFT results were excluded from analysis. Among children with positive QFT, we reported the median IFN-γ level (IU/mL) above background in response to ESAT-6, CFP-10 and TB7.7 at enrollment and follow-up. For QFT results after 1 year, the proportion of children converting from negative to positive and reverting from positive to negative were reported. Incidence rate of TB infection was estimated using positive QFT status at the 1-year follow-up visit among children with negative baseline QFT.
The impact of clinical and epidemiologic covariates on positive QFT at enrollment was assessed using univariable logistic regression. All statistical analyses were performed using Stata 14. A similar proportion of HIV+ and HEU children (12.4% versus 13.2%) reported TB exposure in the year before substudy enrollment. The majority of HIV+ children (84%) were receiving combination antiretroviral therapy and were not immunosuppressed (median CD4% 32%). As the HEU cohort accrued more quickly in the parent study, HIV+ children received less INH or placebo (median 38 versus 96 weeks), were younger and entered the substudy sooner after completing study drug (median 16 versus 73 weeks).
The prevalence of positive QFT was 11.8% (9/76) for HIV+ and 14.4% (19/132) among HEU children at enrolment. At follow-up, prevalence of positive QFT was 14.7% (10/68) for HIV+ and 24.0% (29/121) for HEU children. The median magnitude of IFN-γ response was higher in HEU compared with HIV+ children, but the difference was not statistically significant at both time points (Table, Supplemental Prior TB treatment was associated with a 5.9-fold higher odds of positive QFT for HIV+ children (95% confidence interval: 1.31-26.65; P = 0.02) on univariable logistic regression. Lower HAZ was associated with higher odds of positive QFT among HEU children (odds ratio: 1.69 [1.01-2.78]; P = 0.04). There was no association between INH study arm and QFT positivity among HIV+ or HEU children (Table, Supplemental 
DISCUSSION
We found a high incidence of TB infection among HIV+ and HEU, BCG-vaccinated young children after completing an IPT trial where TB exposure was an initial exclusion criterion. Our observed prevalence of TB infection at baseline was higher than other IGRA studies in HIV+ and HEU in East African children, likely reflecting the higher TB burden and transmission in South Africa. To our knowledge, our study is the first to report incidence of TB infection detected by IGRA in HIV+ and HEU children, and our findings highlight the ongoing high risk of TB exposure and infection in young children born to HIV+ women beyond infancy.
Current WHO guidelines recommend IPT for all children under 5 years of age with reported TB contact; however contact screening alone may miss many TB-exposed children living in TB high burden settings. 8 Despite excluding children with TB exposure at enrolment, there was high incidence of TB disease in the parent trial (12.1 per 100 child-years in HIV+ and 4.1 per 100 child-years in HEU). In our substudy, only 25% of children with positive QFT at baseline reported having a TB contact. Although prior studies in low TB burden settings show poor positive predictive value of IGRA for TB disease in children, 10 a recent study performing serial IGRAs in young South African children found that those with a high magnitude IFN-γ conversion (>4.0 IU/mL) had substantial increased risk of progressing to TB disease (incidence rate ratio: 42.5; P < 0.0001). 7 Half the children in our study with incident TB infection had QFT values >4.0 IU/mL, suggesting that a significant proportion of HIV+ and HEU children with positive QFT are at high risk for TB progression. Future cost-effectiveness assessment of IGRA-targeted screening for TB preventive therapy in HIVexposed children would be beneficial.
Our study had several strengths and limitations. We performed IGRA testing in an appreciable number of young HIV+ and HEU children at baseline and after a year. While our study adds to IGRA data for young HIV+ and HEU children, we have low power to detect small but potentially clinically significant associations. There is no gold standard to define TB infection, therefore, estimates of test performance are not precisely known. Heterogeneity of the HIV+ and HEU cohorts may confound direct comparison of findings between the cohorts. Analyses by IPT arm were performed by intention-to-treat which may have underestimated the effect of IPT. We did not collect data on TB disease history or evaluate for clinical TB disease at follow-up.
In conclusion, we found a high incidence of TB infection in young children born to HIV+ mothers. A substantive proportion of HIV+ and HEU children with incident TB infection had high magnitude of IFN-γ values, indicating risk for TB progression. IGRA gastroenteritis to severe systemic disease affecting, mainly, children. 1, 2 To date, 16 subtypes of HPeV have been described. In pediatric patients, HPeV-1 and HPeV-2 cause mainly mild gastrointestinal and respiratory disease with favorable short-and long-term outcomes.
2,3 HPeV-3 can elicit severe systemic illness including sepsis and central nervous system infection, particularly in young infants.
2,3 Short-term outcomes after HPeV-3 meningoencephalitis are described as reassuring. However, little is known about longterm follow-up and some reports show HPeV-3 as a potential cause for adverse neurodevelopmental outcome. [4] [5] [6] We report the case of a patient with severe long-term neurologic sequelae after a neonatal HPeV-3 meningitis.
CASE PRESENTATION
A male premature neonate was born to a healthy 36-yearold woman, gravida 2/para 1, at 32 weeks and 6 days gestational age. Because of a suspected intrauterine infection due to premature and prolonged rupture of membranes, he was delivered by emergency cesarean section. His birth weight was 2020 g (p50). Apgar score was 2 in the first minute and 8 in the fifth minute. Nine days postpartum, he developed bloody stools and an abdominal radiograph showed pneumatosis intestinalis, indicating necrotizing enterocolitis (NEC). He was admitted to the neonatal intensive care unit and treated with intravenous amoxicillin-clavulanic acid and gentamicin. The clinical course was complicated by a perforation of the bowel. A part of the colon was resected, and a colostomy was performed. Several days later, while still being treated with intravenous amoxicillin-clavulanic acid and gentamicin, the patient showed clinical symptoms of sepsis, without explicit signs of meningitis. Laboratory findings showed elevated C-reactive protein (252 mg/L). Cerebrospinal fluid showed mild pleocytosis (30 leukocytes/3 μL), lowered protein level (0.02 g/L) and normal glucose level (2.1 mmol/L). Intravenous antibiotic therapy was switched to cefotaxime, vancomycin and metronidazole. Bacterial cultures of blood, urine and cerebrospinal fluid were negative. Polymerase chain reaction results revealed HPeV-3, in both cerebrospinal fluid and faeces. On clinical follow-up until term age (37 weeks of age), neurologic examination was normal and repetitive cerebral ultrasounds showed no abnormal findings. However, cerebral magnetic resonance imaging (MRI) at 36 weeks and 3 days of age showed extensive bifrontal periventricular leukomalacia. Our patient clinically recovered and was discharged at 37 weeks and 6 days.
After 1 year, fine motor skills, communication and socialemotional development were assessed by a pediatrician-neonatologist and were in line with his age. However, gross motor skills were delayed and formal neurologic examination showed axial hypotonia and mild hypertonia of the extremities. At 2 years of age, developmental delay was more pronounced in terms of motor skills and social-emotional development. He was assessed with the Bayley-III (Bayley Scales of Infant and Toddler development), which has a normal mean of 100 (standard deviation, 16). The composite cognitive score was 80 [confidence interval (CI): 74-90], and motor skill score was 79 (CI: 73-88). He was referred to a visual rehabilitation clinic because of abnormal visual behavior and decreased visual perception and the diagnosis cerebral visual impairment was confirmed. The patient was referred to a rehabilitation physician and ophthalmologist, and treatments by a physiotherapist and speech therapist were continued. During the following years, he was assessed using the Wechsler Primary Preschool Scale of Intelligence-III-NL, Dutch version, the Movement-Assessment Battery for Children II-NL, and neurologic examinations were performed on a regular basis. Although their contribution to severe disease in young childrensuch as neonatal sepsis and meningoencephalitis-is increasingly recognized, data on long-term consequences are scarce. Here we present the case of a 5-year-old boy with severe long-term neurodevelopmental sequelae after human parechovirus-3 meningitis.
